8-K: Bicycle Therapeutics Unveils Positive Duravelo Data

Bicycle Therapeutics announced encouraging initial Duravelo-2 and updated Duravelo-1 data for metastatic urothelial cancer, showing comparable efficacy to standard of care with a differentiated safety profile.

Summary

• Initial Duravelo-2 data for metastatic urothelial cancer (mUC) at its optimal dose (zelenectide pevedotin 6mg/m2 in combination with pembrolizumab) demonstrated an overall response rate (ORR) of 65% (17/26) and a BICR confirmed ORR of 58% (15/26) at the 27-week interim analysis.
• Subsequent to the 27-week cutoff, an additional confirmed BICR response was observed, which would result in an ORR of 62% (16/26) for Duravelo-2 combination therapy.
• The Duravelo-2 combination therapy showed a median duration of treatment (mDOT) of 6.3 months, with 65% of patients remaining on treatment and a median relative dose intensity of 97%.
• The optimal dose of zelenectide in Duravelo-2 demonstrated a potentially differentiated safety profile with low rates of peripheral neuropathy (33%), skin reactions (17%), and eye disorders (10%), with no reported severe skin reactions or Grade 4/5 zelenectide-related adverse events.
• Updated Duravelo-1 data for zelenectide in combination with pembrolizumab in previously untreated, cisplatin-ineligible mUC patients showed a confirmed ORR of 50% (11/22) and a median progression-free survival (PFS) of 13.0 months.
• Updated Duravelo-1 monotherapy data in EV-naive recurrent, unresectable mUC patients showed a confirmed ORR of 32% (17/53) and a median PFS of 5.4 months.
• Further data from the randomized Phase 2 Duravelo-2 trial are expected in the second half of 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive clinical update, demonstrating comparable efficacy to standard of care with a significantly improved safety and tolerability profile, which is a critical differentiator in oncology.

Positives

• Zelenectide pevedotin in combination with pembrolizumab in Duravelo-2 achieved an overall response rate (ORR) of 65% (17/26) and a BICR confirmed ORR of 62% (16/26) in previously untreated mUC, comparable to published standard of care (SOC) data.
• The optimal dose of zelenectide demonstrated a potentially differentiated safety profile with significantly lower incidence rates for skin reactions (approximately four-fold lower) and peripheral neuropathy (half that) compared to published SOC data.
• Low rates of zelenectide-related adverse events were observed in Duravelo-2 combination therapy, including peripheral neuropathy (33%), skin reactions (17%), and eye disorders (10%), with no severe skin reactions or Grade 4/5 AEs.
• In Duravelo-1, zelenectide in combination with pembrolizumab showed a clinically meaningful median progression-free survival (PFS) of 13.0 months in previously untreated, cisplatin-ineligible mUC, comparable to published SOC data.
• The data validate the potential of Bicycle technology to deliver oncology therapeutics with improved benefit/risk profiles.

Risks

• Uncertainties inherent in research and development and in the initiation, progress, and completion of clinical trials and clinical development of product candidates.
• Risk that Bicycle Therapeutics may not achieve any of its clinical development strategies.
• Timing of results from clinical trials.
• Whether the outcomes of preclinical studies and prior clinical trials will be predictive of future clinical trial results.
• Risk that trials may have unsatisfactory outcomes.
• Potential adverse effects arising from the testing or use of Bicycle Therapeutics product candidates.

Future Outlook

Bicycle Therapeutics plans to share additional data from the randomized Phase 2 Duravelo-2 trial in the second half of 2026. The company aims to continue exploring the advantages of Bicycle molecules with novel targets and payloads to develop oncology therapeutics with improved benefit/risk profiles.

Management Comments

• "We have now tested zelenectide as a monotherapy or in combination with pembrolizumab in more than 600 patients and have consistently observed lower rates and severity of neuropathy and skin toxicities."
• "We believe that the extensive data we have generated in patients continue to demonstrate the unique nature of Bicycle molecules as targeting agents that offer a potentially differentiated tolerability profile to antibody-based approaches."
• "We are excited to continue to explore these advantages with novel targets and novel payloads in our mission to help patients not only live longer but live well."

Industry Context

StockSavvy.ai notes that despite recent advances in bladder cancer treatment, there remains a significant unmet need for more tolerable therapies. Current standard of care for metastatic urothelial cancer often leads to high rates of tolerability-related drug discontinuations, neuropathy, and skin toxicities. Bicycle Therapeutics' zelenectide, with its potentially differentiated safety profile and comparable efficacy, directly addresses this critical gap, positioning it favorably against existing modalities like enfortumab vedotin or pembrolizumab monotherapy, which are associated with higher toxicity.

Comparison to Industry Standards

• Zelenectide in combination with pembrolizumab in previously untreated mUC demonstrated an ORR of 62% (BICR confirmed), which is comparable to published data for standard of care (SOC). For instance, pembrolizumab monotherapy in cisplatin-ineligible mUC has shown ORRs in the range of 20-30%, while combination therapies can achieve higher rates.
• The safety profile of zelenectide showed approximately four-fold lower incidence rates for skin reactions and half that for peripheral neuropathy compared to published data for SOC. For example, enfortumab vedotin, another Nectin-4 targeting ADC, is known for significant skin toxicities and peripheral neuropathy, often leading to dose modifications or discontinuations.
• The median PFS of 13.0 months for zelenectide in combination with pembrolizumab in previously untreated, cisplatin-ineligible mUC is clinically meaningful and comparable to or potentially better than some published SOC regimens for this patient population.

Stakeholder Impact

• Patients: Potential for a new, more tolerable treatment option for metastatic urothelial cancer, offering comparable efficacy with reduced side effects like neuropathy and skin toxicities.
• Shareholders: Positive clinical trial results could lead to increased investor confidence and potential share price appreciation due to the validation of Bicycle technology and the advancement of a key pipeline asset.
• Investment Professionals: Provides critical data for evaluating the company's pipeline, market potential, and competitive positioning in the oncology space.

Next Steps

• Presentation of initial Duravelo-2 data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 June 2, 2026).
• Sharing of further data from the randomized Phase 2 Duravelo-2 trial in the second half of 2026.
• Continued exploration of Bicycle technology with novel targets and novel payloads.

Key Dates

Recommendation

The strong clinical data for zelenectide pevedotin, particularly its comparable efficacy to standard of care combined with a significantly differentiated and improved safety profile, positions Bicycle Therapeutics favorably in the competitive metastatic urothelial cancer market. This validation of their Bicycle technology, coupled with upcoming data releases, suggests substantial upside potential for the stock, making it a strong buy for investors seeking exposure to innovative oncology therapeutics.

Keywords

Bicycle Therapeutics, zelenectide pevedotin, Duravelo-2, Duravelo-1, metastatic urothelial cancer, mUC, Nectin-4, clinical trial, oncology, ASCO, bicyclic peptide, BDC, pembrolizumab, cancer treatment